An Open-Label, Two-Arm (DefenCath® vs. Institutional Standard of Care) Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to Less Than 18 Years of Age With Kidney Failure Receiving Hemodialysis Via a Central Venous Catheter

This study is a post-marketing approval requirement to assess the safety and time to Catheter-related Bloodstream Infections (CRBSI) of DefenCath in pediatric population (birth to less than 18 years of age) who are on chronic HD for kidney failure.

Start Date08 Jul 2025

Sponsor / Collaborator

CorMedix, Inc.

NCT06453876

/ Not yet recruitingPhase 3IIT

Percutaneous Embolectomy, Ultrasund Assisted Low Dose Thrombolysis or Heparin for Intermediate High Risk Pulmonary Embolism

The STRATIFY II trial investigates the efficacy of three different approaches to reducing thrombus burdon in patients with acute intermediate high-risk pulmonary embolism: percutaneous embolectomy (the Flow Triever® system, INARI medical), USAT (EKOS® system, Boston Scientific with low dose alteplase) and heparin with the option to perform full-dose thrombolysis. As a co-primary secondary end point the trial assess the incremental efficacy of the embolectomy vs the catheter based low dose thrombolysis approach.
Thus the two main hypothesis being tested are:
1. Thrombus burden reduction after 48-96 h is increased with a catheter based (embolectomy or USAT) compared to the a heparin with optional high dose thrombolysis approach (1st co-primary outcome)
2. Thrombus burden reduction after 48-96 h is increased with percutaneous embolectomy compared to USAT with low-dose alteplase (2nd co-primary outcome)

Start Date01 Jun 2025

Sponsor / Collaborator

Rigshospitalet

[+2]

NCT06845423

/ RecruitingPhase 4IIT

Prevention of Postpartum Venous Thromboembolism in Women at Intermediate Risk. An Open-label, Randomized, Controlled Trial Comparing Two Strategies With or Without Pharmacological Thromboprophylaxis

Venous thromboembolism (VTE) is currently the second cause of death in women of reproductive age worldwide. The incidence of VTE during pregnancy is 1.2 to 1.4/1000 women, half of VTE occurring during postpartum and as PE in majority of cases, accounting for 8.8% of maternal deaths.
Majority of postpartum VTE occurs in women with one or more moderate risk factors (obesity, caesarean section, postpartum hemorrhage). For these women at intermediate risk, the efficacy and safety of thromboprophylaxis have not been assessed yet during postpartum and international guidelines for pharmacological thromboprophylaxis, based on data extrapolated from other populations, observational studies and small clinical trials are inconsistent across countries.
We designed an open-label, randomized, controlled trial, aiming to demonstrate the superiority of a pharmacological thromboprophylaxis strategy with LMWH (LMWH type chosen according to physician / patient's preference) during 6 weeks after delivery (the 6-weeks follow-up visit being matched with usual care) in women at intermediate risk, over no pharmacological thromboprophylaxis.

Start Date16 May 2025

Sponsor / Collaborator

University Hospital of Brest

100 Clinical Results associated with Heparin Calcium

100 Translational Medicine associated with Heparin Calcium

100 Patents (Medical) associated with Heparin Calcium

56,936

Literatures (Medical) associated with Heparin Calcium

01 Jan 2026·ANNALS OF VASCULAR SURGERY

One-Year Functional Patency and Comparison of Superficialization Techniques for Brachiobasilic Arteriovenous Fistulas

Article

Author: Sandigo-Saballos, Isabela ; Hurwitz, Mikayla ; Archie, Mark ; Valadez, Maria ; Ugarte, Ramsey ; Montero Arcila, Veronica ; de Virgilio, Christian

BACKGROUND:

Superficialization of brachiobasilic arteriovenous fistulae (BBAVFs) is generally performed by either creating a shelf or dividing, tunneling, and transposing the vein with reanastomosis. This multiinstitutional study evaluates the impact of these techniques and other variables on BBAVF functional patency at 12 months.

METHODS:

A retrospective review of patients who underwent two-stage BBAVF between 2014 and 2019 with at least 1-year follow-up was conducted from 5 safety net hospitals. The primary end point was functional patency at 12 months. Bivariate and multivariate logistic regression models evaluated the relationship between preoperative and intraoperative variables and fistula function at 12 months.

RESULTS:

There were 260 patients with an overall 12-month functional patency rate of 71.5%. Use of aspirin (odds ratio [OR] 1.858, 95% confidence interval [CI] 1.023-3.372, P = 0.042) and intraoperative anticoagulation (OR 2.118, 95% CI 1.193-3.760, P = 0.01) at the first stage procedure, and previous arteriovenous fistula or graft (OR 0.465, 95% CI 0.233-0.928, P = 0.030), were associated with functional patency at 12 months. When comparing shelfing versus transposition techniques, there was no significant difference in the functional patency rates (83.6% vs. 89.9%, P = 0.179), although the shelfing technique was associated with a higher rate of postoperative complications (19.8% vs. 9.0%, P = 0.027).

CONCLUSION:

In patients undergoing 2-stage BBAVF, the use of aspirin and intraoperative heparin at the first stage procedure are associated with higher functional patency at 12 months. Functional patency was similar for the shelfing technique versus transposition at the second stage. The shelfing technique was associated with higher rates of postoperative complications, primarily related to wound healing.

01 Jan 2026·ANNALS OF VASCULAR SURGERY

Safety and Efficacy of Bivalirudin as a Heparin Alternative in Patients Undergoing Carotid Artery Stenting

Article

Author: Maningat, Alexandra L ; Lewis, Anthony J ; Shah, Sahaj ; Elmore, James ; Guo, Tian ; Salzler, Gregory G ; Ryer, Evan J ; Kania, Thomas A

BACKGROUND:

Transfemoral carotid artery stenting (TFCAS) and transcarotid artery revascularization (TCAR) are commonly used to treat carotid stenosis. However, the need for heparin alternatives during these procedures and their impact on outcomes remain unclear. This study evaluates the safety and efficacy of bivalirudin, the most commonly used heparin alternative, compared to heparin.

METHODS:

The Vascular Quality Initiative registry was queried for carotid artery stenting procedures performed from 2010 to 2022. Propensity-matched analyses compared outcomes between patients receiving intraprocedural heparin and those receiving bivalirudin. Primary outcomes were postoperative neurological events, including stroke or transient ischemic attack, and bleeding. Secondary outcomes included 30-day rates of reintervention and myocardial infarction, and mortality at 30 days and 1 year.

RESULTS:

Among 80,172 carotid artery stenting procedures, 2,789 (3.47%) were performed with bivalirudin. In the heparin group, 24,797 (34.1%) underwent TFCAS with distal embolic protection, while 47,961 (65.9%) underwent TCAR with flow reversal. In the bivalirudin group, 2,494 (91.2%) underwent TFCAS, and 240 (8.8%) underwent TCAR. Propensity matching created 2 cohorts of 957 patients each. There were no significant differences in neurological events (odds ratio, [OR]: 1.44, 95% confidence interval [CI]: 0.72-2.86; P = 0.30), bleeding (OR: 1.0, 95% CI: 0.53-1.90; P = 1.00), 30-day mortality (OR: 2.05, 95% CI: 0.62-6.85; P = 0.24), or 1-year mortality (OR: 1.37, 95% CI: 0.84-2.24; P = 0.21).

CONCLUSION:

Bivalirudin is a safe and effective alternative to heparin for patients with contraindications to heparin undergoing carotid artery stenting. These findings suggest no significant differences in outcomes, supporting bivalirudin as a viable anticoagulation option.

31 Dec 2025·ANNALS OF MEDICINE

Low-dose heparin sodium as a protective factor against bronchiolitis obliterans formation after adenovirus infection

Article

Author: Hu, Rong ; Cui, Lei ; Ding, Xiaofang ; Peng, Li ; Zhong, Lili ; Lin, Lin ; Huang, Han ; Liu, Silan ; Chen, Min

BACKGROUND:

Adenovirus (ADV) pneumonia in children is a significant contributor to the occurrence of post-infectious bronchiolitis obliterans (BO). Heparin sodium has known anti-inflammatory, immunomodulatory, and tissue repair properties. However, its role in treating BO after ADV infection remains unclear.

METHODS:

A retrospective analysis was conducted on 793 children diagnosed with ADV pneumonia and hospitalized in the southern region from January 2019 to December 2019. Among them, 307 cases were classified as single ADV pneumonia. We utilized directed acyclic graphs to analyze the causal relationships between various variables, which further helped us identify the independent and confounding variables for constructing our regression model. Propensity score matching (PSM) was also employed to control for confounding variables that could not be intervened in this study, ensuring baseline level equilibrium and correction. We utilized univariate logistic regression analysis to explore the factors influencing BO development after ADV pneumonia.

RESULTS:

Among the 793 children diagnosed with ADV pneumonia, 86 cases (10.84%) progressed to BO. The proportion of heparin use was higher in the non-BO group than in the BO group after PSM. The univariate regression analysis revealed that acute respiratory failure, neurological involvement and fibrinogen (FIB) were risk factors for the development of BO in ADV pneumonia cases (OR > 1, p < 0.05), but low-dose heparin sodium treatment and hemoglobin (OR < 1, p < 0.05) exhibited protective effects against BO formation. Among the 307 children with single ADV pneumonia (excluding confounding factors), 33 cases (10.75%) developed BO. The univariate regression analysis further indicated that fever duration, acute respiratory failure and FIB were risk factors for the development of BO in single ADV pneumonia (OR > 1, p < 0.05), while low-dose heparin sodium treatment (OR < 1, p < 0.05) was protective against BO formation after a single ADV pneumonia.

CONCLUSION:

Low-dose heparin sodium treatment may be a protective factor against the development of BO after ADV pneumonia infection.

258

News (Medical) associated with Heparin Calcium

18 Jul 2025

·www.prnewswire.com

B. Braun Expands Heparin Sodium Injection Portfolio to Seven Heparin Premixed Sodium Injection Products

BETHLEHEM, Pa., July 18, 2025 /PRNewswire/ -- B. Braun Medical Inc. (B. Braun), a leader in smart infusion therapy and pain management, announced today the launch of its new Heparin Sodium Injections into the U.S. market, expanding its portfolio to include 25,000 Units Heparin in 0.45% Sodium Chloride Injection (50 units/mL) and 25,000 Units Heparin in 0.45% Sodium Chloride Injection (100 units/mL). These launches expand B. Braun's portfolio to become the largest offering of Heparin Premixed bags in the U.S. market. The 250 mL and 500 mL bags will feature a 2D enhanced barcode. The 2D enhanced barcode design includes the National Drug Code (NDC) number, lot number and expiration date, along with increased spacing between the two 1D barcodes. These enhancements are designed to help improve the accuracy and efficiency of barcode scanning. The B. Braun Heparin portfolio is manufactured using EXCEL® IV Containers, which are not made with DEHP, PVC or natural rubber latex, prioritizing patient and environmental safety. The product is produced and distributed from B. Braun's Irvine, California pharmaceutical manufacturing facility. "Expanding our Heparin Sodium Injection portfolio underscores our commitment to healthcare providers and their patients. By offering the largest selection of premixed Heparin products in the market, we are helping to provide healthcare workers with the tools they need to deliver precise and effective care," said Shawn Brinson, Director of Marketing, Injectable Drugs, B. Braun Medical Inc. Heparin Sodium 25,000 Units Heparin in 0.45% Sodium Chloride Injection (50 units/mL) and Heparin Sodium 25,000 Units Heparin in 0.45% Sodium Chloride Injection (100 units/mL), are indicated as anticoagulants to maintain catheter patency. For additional information, please see full Prescribing Information. IMPORTANT SAFETY INFORMATION Contraindications: History of heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis (HITT) Known hypersensitivity to heparin or pork products (e.g., anaphylactoid reactions) In whom suitable blood coagulation tests — e.g., the whole blood clotting time, partial thromboplastin time, etc., — cannot be performed at appropriate intervals (this contraindication refers to full-dose heparin; there is usually no need to monitor coagulation parameters in patients receiving low-dose heparin) Uncontrollable active bleeding state except when this is due to disseminated intravascular coagulation About B. Braun B. Braun Medical Inc. (B. Braun) is a leader in smart infusion therapy and safe and effective pharmacy products, patient and provider safety, and sustainable health solutions. Our purpose is to help providers constantly improve patient satisfaction and outcomes. With products and services created to help healthcare professionals focus on what matters most—their patients—we're uniquely positioned to help health systems succeed now and in the future. B. Braun is headquartered in Bethlehem, Pennsylvania and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap® and CAPS®. The company employs 8,500 people at over 30 locations across North America. Globally, the B. Braun Group of Companies employs more than 64,000 employees in 64 countries. Guided by its Sharing Expertise® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, explore our website. SOURCE B. Braun Medical Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

27 Jun 2025

·www.globenewswire.com

CorMedix Inc. Announces Pricing of Public Offering of Common Stock

BERKELEY HEIGHTS, N.J., June 27, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced the pricing of its previously announced underwritten public offering of 6,604,507 shares of its common stock. The total gross proceeds from the offering to the Company are expected to be approximately $85 million. In addition, CorMedix granted the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the offering. The closing of the offering is expected to occur on or about June 30, 2025, subject to the satisfaction of customary closing conditions. RBC Capital Markets is acting as sole bookrunner for the offering. Truist Securities, Citizens Capital Markets, and Needham & Company are acting as capital markets advisors for the offering. CorMedix intends to use the net proceeds from the offering for general corporate purposes, which may include working capital, expenses related to research and the development of product candidates, and potential strategic transactions, including acquisitions, joint ventures or collaborations, involving companies, products or assets that complement CorMedix’s business. The securities described above are being offered by CorMedix pursuant to a shelf registration statement on Form S-3 which was initially filed by CorMedix with the Securities and Exchange Commission (the “SEC”) May 6, 2024, and was declared effective by the SEC on May 22, 2024. The securities will be offered only by means of a prospectus supplement and accompanying prospectus relating to the offering that form a part of the registration statement. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website at http://www.sec.gov. Copies of the preliminary prospectus supplement and accompanying base prospectus relating to the offering, as well as copies of the final prospectus supplement, when available, may be obtained from RBC Capital Markets, LLC, Attention: Equity Capital Markets, 200 Vesey Street, 8th Floor, New York, NY 10281, by telephone at (877) 822-4089, or by email at equityprospectus@rbccm.com. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer or sale will be made only by means of CorMedix’s prospectus supplement and prospectus forming part of the effective registration statement relating to these securities. About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath® (taurolidine and heparin) which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix is commencing clinical studies in Total Parenteral Nutrition and Pediatric patient populations in 2025 and also intends to develop DefenCath as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to risks and uncertainties, including expectations regarding the offer and sale of common stock, the terms of the offering, the expected use of proceeds, timing of implementation, patient utilization and enrollment, the timing and volume of increased shipments, and expectations regarding future growth opportunities. Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “will,” “plan,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions or variations intended to identify forward-looking statements. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or CorMedix’s prospects should be considered forward-looking statements. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including the risks and uncertainties related to market conditions; satisfaction of customary closing conditions related to the offerings and the risks and uncertainties in the Risk Factors identified in CorMedix’s filings with the SEC, including its most recent Annual Report on Form 10-K and its Quarterly Report on Form 10-Q, and the preliminary prospectus supplement related to the proposed public offering, copies of which are available free of charge at the SEC’s website at www.sec.gov or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and such forward-looking statements speak only as of the date of this press release. Investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law. Investor Contact:Dan FerryManaging DirectorLifeSci Advisorsdaniel@lifesciadvisors.com(617) 430-7576

Drug ApprovalClinical Study

27 Jun 2025

·cormedix.com

CORMEDIX INC. ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

Berkeley Heights, NJ – June 27, 2025 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced the pricing of its previously announced underwritten public offering of 6,604,507 shares of its common stock. The total gross proceeds from the offering to the Company are expected to be approximately $85 million. In addition, CorMedix granted the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the offering. The closing of the offering is expected to occur on or about June 30, 2025, subject to the satisfaction of customary closing conditions. RBC Capital Markets is acting as sole bookrunner for the offering. Truist Securities, Citizens Capital Markets, and Needham & Company are acting as capital markets advisors for the offering. CorMedix intends to use the net proceeds from the offering for general corporate purposes, which may include working capital, expenses related to research and the development of product candidates, and potential strategic transactions, including acquisitions, joint ventures or collaborations, involving companies, products or assets that complement CorMedix’s business. The securities described above are being offered by CorMedix pursuant to a shelf registration statement on Form S-3 which was initially filed by CorMedix with the Securities and Exchange Commission (the “SEC”) May 6, 2024, and was declared effective by the SEC on May 22, 2024. The securities will be offered only by means of a prospectus supplement and accompanying prospectus relating to the offering that form a part of the registration statement. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website at http://www.sec.gov. Copies of the preliminary prospectus supplement and accompanying base prospectus relating to the offering, as well as copies of the final prospectus supplement, when available, may be obtained from RBC Capital Markets, LLC, Attention: Equity Capital Markets, 200 Vesey Street, 8th Floor, New York, NY 10281, by telephone at (877) 822-4089, or by email at equityprospectus@rbccm.com. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer or sale will be made only by means of CorMedix’s prospectus supplement and prospectus forming part of the effective registration statement relating to these securities. About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath® (taurolidine and heparin) which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix is commencing clinical studies in Total Parenteral Nutrition and Pediatric patient populations in 2025 and also intends to develop DefenCath as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to risks and uncertainties, including expectations regarding the offer and sale of common stock, the terms of the offering, the expected use of proceeds, timing of implementation, patient utilization and enrollment, the timing and volume of increased shipments, and expectations regarding future growth opportunities. Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “will,” “plan,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions or variations intended to identify forward-looking statements. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or CorMedix’s prospects should be considered forward-looking statements. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including the risks and uncertainties related to market conditions; satisfaction of customary closing conditions related to the offerings and the risks and uncertainties in the Risk Factors identified in CorMedix’s filings with the SEC, including its most recent Annual Report on Form 10-K and its Quarterly Report on Form 10-Q, and the preliminary prospectus supplement related to the proposed public offering, copies of which are available free of charge at the SEC’s website at www.sec.gov or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and such forward-looking statements speak only as of the date of this press release. Investors should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law. Investor Contact: Dan Ferry Managing Director LifeSci Advisors daniel@lifesciadvisors.com (617) 430-7576

Drug ApprovalClinical Study

100 Deals associated with Heparin Calcium

External Link

KEGG	Wiki	ATC	Drug Bank
D04427	Heparin Calcium	S01XA14 B01AB01 C05BA03	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Blood Coagulation Disorders	China	Sanofi Winthrop Industrie SA	07 Dec 2000
Venous Thromboembolism	China	Sanofi Winthrop Industrie SA	07 Dec 2000

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pulmonary Disease, Chronic Obstructive	Phase 2	United Kingdom	Ockham Biotech Ltd.	30 Jan 2022
Cystic Fibrosis	Phase 1	United Kingdom	Ockham Biotech Ltd.	30 Jan 2022
Diabetes Mellitus, Type 1	Phase 1	Germany	Sanofi	17 Feb 2017
Asthma	Preclinical	United Kingdom	Ockham Biotech Ltd.	30 Jan 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ATS2025	Not Applicable	Chronic thromboembolic pulmonary hypertension heparin anti-platelet-factor (PF)-4 antibody \| lupus anticoagulant \| cold agglutinins antibodies	1,087	Heparin (Control group of non-PF4+ PTE patients)	mvzcnedwam(dyhhrrupfs) = no difference across groups loagyqfbcz (ibwfhftuex ) View more	-	16 May 2025
Inha University Hospital Stroke Prospective Registry (ISC2025)	Not Applicable	Thrombosis	460	Heparin during MT	llymevhqgs(xymxcvvmqr) = ezdqqsyxci qjmlbkzmmk (agtuvolgkg, 12.5)	Negative	30 Jan 2025
				No Heparin during MT	llymevhqgs(xymxcvvmqr) = eohzhdvfep qjmlbkzmmk (agtuvolgkg, 10.1)
ESC2024	Not Applicable	Glucose Metabolism Disorders	-	Heparin premedication	enhxobvebz(mcfogmtycf) = najyyaxvpa fwxeiytdgr (genrpuxncb )	-	30 Aug 2024
				No heparin premedication	enhxobvebz(mcfogmtycf) = ttkennomml fwxeiytdgr (genrpuxncb )
ATS2024	Not Applicable	Hematoma	-	Heparin infusion	lxanqwixwr(beuhzzgzta) = SPH in a patient on heparin was first described in 1996, almost 80 years after heparin was first used. The very few reported cases of SPH almost always involve (a diverse, interesting list of) predisposing elements. Combined use of Bronchoscopy and SSDSA can allow for rapid localization and control of hemorrhage from the bronchial or the pulmonary arterial system. Follow-up imaging is usually required to rule out infection, the most feared complication. snxrpmcgkr (wtabxnclsp )	-	19 May 2024
NCT02984384 (PREVENT CLOT, CTgov)	Phase 3	Thrombosis \| Wounds and Injuries	12,424	Low Molecular Weight Heparin (Low Molecular Weight Heparin (LMWH)-Enoxaparin)	zxwpzswnfe = yiwwtlzuio kjhqsjvfkd (tucoacrtvc, ktokescxwd - rycoymruog) View more	-	14 May 2024
				Acetylsalicylic acid (Acetylsalicylic Acid (ASA)-Aspirin)	zxwpzswnfe = pyepkqxcpb kjhqsjvfkd (tucoacrtvc, uiktuhkhyr - qssnhhetbs) View more
AAN2024	Not Applicable	Heparin-induced thrombocytopenia and thrombosis	-	Heparin (Ocular Ischemic Syndrome (OIS))	hcmoqowevh(uumvzryavz) = OIS is a rare complication of HITT, occurring within two weeks of repeat exposure to heparin following initial exposure within three months. Awareness of both conditions is crucial to guide prompt management and optimal care to prevent neurologic sequelae. wuqdqfpovu (kirztwjshz )	-	09 Apr 2024
ESC2024	Not Applicable	Shock, Cardiogenic	-	heparin (Normal fibrinogen levels and normal INR)	ehwqheygeu(hunrzzvajl) = zxqdtduaxt yqngyafvwb (cqvkzwtlvi )	-	09 Mar 2024
				heparin (Reduced fibrinogen levels and/or prolonged INR)	ehwqheygeu(hunrzzvajl) = evethaobpj yqngyafvwb (cqvkzwtlvi )
PERIOP-01 (ASH2023)	Not Applicable	Colorectal Cancer	614	Extended duration thromboprophylaxis with low-molecular-weight-heparin	briifxbvoa(pwrtbgcveo) = muyucxdhfq hthdqghwsp (kflfwzqihb ) View more	-	10 Dec 2023
				Standard duration thromboprophylaxis	briifxbvoa(pwrtbgcveo) = igsapdjffh hthdqghwsp (kflfwzqihb ) View more
ESC2023	Not Applicable	-	768	Heparin dose 50IU/kg	mllfhpqztm(xrpulilmdd) = gepsiigkng zexdkfauia (avjafusmzt )	-	27 Aug 2023
				Heparin dose ≥70IU/kg	mllfhpqztm(xrpulilmdd) = hrbjmoobtb zexdkfauia (avjafusmzt )
ATS2023	Not Applicable	Thrombosis	-	Heparin	rrxnbmfvyz(jznucigwrd) = Frequently described complications of HIT thrombosis (HITT) include arterial thromboembolism including acute limb ischemia, myocardial infarction and venous thromboembolism. Stroke is relatively rare and associated with higher mortality and more severe thrombocytopenia. Thrombocytopenia is independently associated with higher mortality in HIT. bsojawmujh (lgdbfbkrje ) View more	-	21 May 2023
				Argatroban

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Heparin Calcium

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation